Ceribell initiated with a Buy at BTIG

BTIG analyst Marie Thibault initiated coverage of Ceribell (CBLL) with a Buy rating and $30 price target “Ceribell has developed the point-of-care Ceribell System for rapid electroencephalogram monitoring, the analyst tells investors in a research note. The firm says the system uses the company’s proprietary artificial intelligence-driven Clarity algorithm, the first to receive an on-label indication for the diagnosis of electrographic status epilepticus, defined as a seizure lasting continuously for over five minutes. While still in the early stages of commercialization, Ceribell is “poised for growth,” contends BTIG.